INVESTOR NEWS

Presentation of 2021 first quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2021 first quarter results on April 16th at 10.00 am. The..

Publication of NT-proBNP patent application

4Q 2020 Results and preliminary annual report

Moss, 11 February 2020 Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary..

Presentation of 2020 fourth quarter results for Gentian Diagnostics AS

Moss, 05 FEB 2021

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..

Gentian Diagnostics presents at the DNB Nordic Healthcare Conference

Moss, 15.12.20

Gentian and research partners with two posters related to the value of calprotectin in management of COVID-19 patients at the AACC

Moss, 14.12.2020

Financial Calendar

Financial calendar for Gentian Diagnostics AS

New study results confirm the value of calprotectin in management of COVID-19 patients (2020)

Moss, Norway 20.11.2020 Gentian Diagnostics AS is pleased to announce that the results from a study conducted..

Gentian Diagnostics divests its subsidiary PreTect AS

Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS to Mel-Mont Medical, Inc...